Alcon takes another step towards WaveLight acquisition

Article

The German Federal Financial Supervisory Authority has approved publication of Alcon's tender offer document for WaveLight AG. This tender offer marks the second step in the completion of Alcon's acquisition of WaveLight.

The German Federal Financial Supervisory Authority has approved publication of Alcon's tender offer document for WaveLight AG. This tender offer marks the second step in the completion of Alcon's acquisition of WaveLight.

Alcon hopes to increase its stake in WaveLight from 16% of issued shares to at least 75% and, in response to recent trading activity, Alcon has increased its previously announced offer for WaveLight from €10 to €15 per share. The tender offer acceptance period closes on 11th September, 2007.

Alcon isn't the only firm to express an interest in WaveLight, however. Carl Zeiss Meditec has also acquired a 5% shareholding in the firm. The company says that the acquisition of stock demonstrates its interest in a possible voluntary takeover offer. Zeiss believes any takeover would be based on the future earning potential of Wavelight and the possible benefits that could arise from combining the two businesses.

On 20th August, WaveLight's Executive Committee and Supervisory Board recommended that shareholders tender their shares to Alcon.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.